Overview
Lobbying Costs
400,000€ - 499,999€
Financial year: Jan 2021 - Dec 2021
Lobbyists (Full time equivalent)
1.4 Fte (6)
Lobbyists with EP accreditation
0
High-level Commission meetings
7
Lobbying Costs over the years
-
Info
Novo Nordisk A/S
EU Transparency Register
29570313329-11 First registered on 13 Mar 2010
Goals / Remit
Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat. We employ more than 47,000 people in 80 offices around the world, and market our products in 168 countries. Novo Nordisk is committed to developing its business towards environmental, social and financial sustainability (the triple bottom line). This commitment is demonstrated through its values and its environmental and social responsibility policies. The Novo Nordisk Foundation is a non-profit institution, whose formal purpose is to provide a stable basis for its companies’ operations and to make contributions to scientific, humanitarian and social progress.
Main EU files targeted
EU pharmaceutical-related legislation (in the fields of health, research and technology, IHI, environment, enterprise and trade).
Address
Head Office
Novo Nordisk A/S Novo Allé, 1
Bagsværd 2880
DENMARKEU Office
Square de Meeûs 37
Brussels null - 1000
BELGIUMWebsite
-
People
Total lobbyists declared
6
Employment time Lobbyists 75% 1 25% 1 10% 4 Lobbyists (Full time equivalent)
1.4
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
0 accreditations were / are live (in bold) for the selected state of 13 May 2022
Name Start date End Date Mr Matthew Thomas Vincent CLAY 27 Oct 2023 25 Oct 2024 Ms Helen Oberg 12 Apr 2023 11 Apr 2024 Mr Christian JUUL NYHUS 16 Feb 2023 16 Feb 2024 Mr Alexander VON WILDENRATH LØVGREEN 16 Feb 2023 16 Feb 2024 Mr Matthew CLAY 07 Jun 2022 07 Jun 2023 Mr Vincent CLAY 07 Jun 2022 27 Jun 2022 Jeppe Torp VESTENTOFT 03 Dec 2019 01 Aug 2020 Ms Victoria Breck 30 Nov 2019 28 Nov 2020 Ms Ane Sofie Böhm Nielsen 23 Sep 2014 19 Sep 2015 Mr Troels Anders RYE-ANDERSEN 08 Aug 2014 06 Aug 2015 Mr Morten Frank Pedersen 19 Sep 2013 18 Sep 2014 Ms Engelbertha Maria Rouweler 17 Sep 2013 14 Mar 2014 Mr Neil David Causey 17 Sep 2013 14 Sep 2014 Mr Troels Anders RYE-ANDERSEN 07 Jun 2013 06 Jun 2014 Mr Troels Anders RYE-ANDERSEN 16 Jan 2012 08 Feb 2013 Complementary Information
A range of Novo Nordisk colleagues contribute their expertise to activities covered by the Register, directly or through trade associations. We have used 10% relevant working time as the threshold for including colleagues in our FTE calculations.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
Novo Nordisk is member of:
EFPIA - European Federation of Pharmaceutical Industries and Associations
Danish Chamber of Commerce
MedTech Europe
IFPMA - International Federation of Pharmaceutical Manufacturers & Associations
Science|BusinessMember organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2021 - Dec 2021
Lobbying costs for closed financial year
400,000€ - 499,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount rud pedersen 10,000€ - 24,999€ Intermediaries for current year
None declaredClosed year Costs
400,000€ - 499,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
The Twitter account of our CEO, Lars Fruergaard Jørgensen, may sometimes include content relevant to activities covered by the Register: @LarsFruergaard
In January 2022, Politico Europe published sponsored content from EFPIA, authored by Lars Fruergaard Jørgensen: https://www.politico.eu/sponsored-content/safeguarding-the-supply-of-medicines-to-patients-in-europe/Other activities
Novo Nordisk's goals with its involvement with EU institutions are:
- to improve conditions for prevention, treatment and care in Europe to address unmet needs
- to support the voice of people living with or at risk of developing serious chronic diseases
- to increase Europe´s competitiveness as a location for Research and Development- Meetings
Meetings
7 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 17 Jan 2024 Location Davos Subject Meeting with Ms Camilla Sylvest, Executive Vice-President. Cabinet Cabinet of Commissioner Stella Kyriakides Attending - Giorgios Rossides (Cabinet member)
- Stella Kyriakides (Commissioner)
-
Date 30 Mar 2023 Location Brussels, Belgium Subject The discussion will be focused on the up-coming legislation on plants produced by certain genomic techniques, and the revision of plant-proteins. Cabinet Cabinet of Commissioner Janusz Wojciechowski Portfolio Agriculture Attending - Jorge Pinto Antunes (Cabinet member)
Other Lobbyists -
Date 06 Dec 2022 Location Brussels Subject Revision of the EU pharmaceutical legislation. Cabinet Cabinet of Executive Vice-President Margrethe Vestager Portfolio Europe Fit for Digital Age Attending - Pierre-Arnaud Proux (Cabinet member)
-
Date 16 Sep 2021 Location Brussels Subject Discussion with EFPIA and Novo Nordisk on how the pharmaceutical industry could contribute to the EU's agenda for open strategic autonomy and the renewed industrial strategy and on the green transformations of the pharmaceutical sector. DG Internal Market, Industry, Entrepreneurship and SMEs Attending - Kerstin Jorna (Director-General)
-
Date 16 Jun 2021 Location online Subject Supply chains for medicines Cabinet Cabinet of Vice-President Margaritis Schinas Portfolio Promoting the European Way of Life Attending - Maria Luisa Llano Cardenal (Cabinet member)
- Margaritis Schinas (Vice-President)
Other Lobbyists - Teva Pharmaceuticals Europe BV
- European Healthcare Distribution Association
- SANOFI
- Bureau Européen des Unions de Consommateurs
- Phamaceutical Group of the European Union
- Pfizer Inc.
- European Federation of Pharmaceutical Industries and Associations
- The European Association of Hospital Pharmacists
- Fresenius Kabi Deutschland GmbH
- European Chemical Industry Council
- European Patients' Forum (EPF)
- Medichem, S.A.
- MEDICINES FOR EUROPE
- Leuphana Universität Lüneburg
-
Date 21 May 2021 Location Copenhagen Subject Industrial Strategy Cabinet Cabinet of Executive Vice-President Margrethe Vestager Portfolio Europe Fit for Digital Age Attending - Margrethe Vestager (Executive Vice-President)
Other Lobbyists -
Date 25 Jan 2021 Location Brussels Subject Commission’s priorities for digital and industrial policy in 2021 Cabinet Cabinet of Executive Vice-President Margrethe Vestager Portfolio Europe Fit for Digital Age Attending - Michele Piergiovanni (Cabinet member)
- Christiane Canenbley (Cabinet member)
Other Lobbyists
- Meetings